Novozymes is the world leader in bioinnovation, producing a wide range of industrial enzymes, microorganisms, and biopharmaceutical ingredients.
25. April 2013
The first quarter of 2013 was in line with expectations. Organic sales growth was 5% (4% DKK, 5% LCY) compared with Q1 2012. EBIT grew by 4%, and the EBIT margin was 24.9% – on par with the first quarter of 2012.
28. February 2013
Reduction of the company’s share capital by cancellation of a part of its holding of treasury B shares. The company’s B share capital is reduced by DKK 10,600,000 from DKK 542,512,800 to DKK 531,912,800.
1. April 2013
26. February 2013
| Copyright © 2010 Novozymes. All Rights Reserved.